Company intelligence / Profile preview

Recombination Therapeutics

Philadelphia, Pennsylvania, United Statesrecombinationtx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company is developing POLQ inhibitors for cancer treatment. Recent research was presented with Thomas Jefferson University on new POLQ inhibitors in July 2024[6].

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

Undisclosed Polq inhibitor

Pre-clinical

Indications: Cancer, BRCA1/2-mutated cancers

1 more asset in the full pipeline.

Request access →

Partnerships

Thomas Jefferson University[6]

Beyond the preview

Go deeper on Recombination Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Recombination Therapeutics.

Explore the full profile